We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+9.96%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$25.2B
AUM Growth
-$335M
(-1.3%)
Cap. Flow
-$2.05B
Cap. Flow
% of AUM
-8.13%
Top 10 Holdings %
Top 10 Hldgs %
26.87%
Holding
1,147
New
127
Increased
298
Reduced
504
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$160M |
| 2 |
Masco
MAS
|
+$134M |
| 3 |
Lam Research
LRCX
|
+$112M |
| 4 |
Coupang
CPNG
|
+$101M |
| 5 |
Nu Holdings
NU
|
+$98.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE Vernova
GEV
|
+$205M |
| 2 |
Lennox International
LII
|
+$191M |
| 3 |
NVIDIA
NVDA
|
+$169M |
| 4 |
Tractor Supply
TSCO
|
+$157M |
| 5 |
Apple
AAPL
|
+$151M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.69% |
| 2 | Consumer Discretionary | 12.85% |
| 3 | Industrials | 12.71% |
| 4 | Financials | 12.68% |
| 5 | Healthcare | 9.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Aurinia Pharmaceuticals
AUPH
$1.92B
| $13.5M | 0.05% |
1,219,451
+471,338
| +63% | +$5.15M |
|
252
Herbalife
HLF
$1.28B
| $13.5M | 0.05% |
1,595,762
-360,108
| -18% | -$3.4M |
|
|
MZTI
253
The Marzetti Company
MZTI
$3.07B
| $13.4M | 0.05% |
77,626
+1,762
| +2% | +$316K |
|
254
Northern Trust
NTRS
$22.1B
| $13.3M | 0.05% |
98,529
-72,800
| -42% | -$9.37M |
|
255
FIGS
FIGS
$1.75B
| $13.2M | 0.05% |
1,976,705
+422,277
| +27% | +$2.79M |
|
256
Avista
AVA
$3.44B
| $13.2M | 0.05% |
348,964
-128,640
| -27% | -$4.78M |
|
257
Bank of N.T. Butterfield & Son
NTB
$2.41B
| $12.9M | 0.05% |
300,469
-738
| -0.2% | -$33.3K |
|
258
DNOW Inc
DNOW
$2.45B
| $12.6M | 0.05% |
826,219
-49,707
| -6% | -$750K |
|
259
American Express
AXP
$226B
| $12.5M | 0.05% |
37,649
-21,802
| -37% | -$6.93M |
|
260
Kforce
KFRC
$1.09B
| $12.3M | 0.05% |
411,706
+243,303
| +144% | +$8.62M |
|
261
CarGurus
CARG
$3.34B
| $12.2M | 0.05% |
+327,025
| New | +$11.2M |
|
262
WD-40
WDFC
$3.02B
| $11.9M | 0.05% |
60,217
+1,447
| +2% | +$313K |
|
263
Cal-Maine
CALM
$4.44B
| $11.9M | 0.05% |
126,430
+80,253
| +174% | +$8.57M |
|
264
Boise Cascade
BCC
$2.7B
| $11.9M | 0.05% |
153,484
-119,702
| -44% | -$10.2M |
|
265
Lifestance Health
LFST
$4.25B
| $11.8M | 0.05% |
2,147,690
+38,528
| +2% | +$189K |
|
266
JELD-WEN Holding
JELD
$103M
| $11.8M | 0.05% |
2,397,359
+580,001
| +32% | +$3.1M |
|
267
Phinia Inc
PHIN
$2.99B
| $11.7M | 0.05% |
203,424
-21,571
| -10% | -$1.16M |
|
|
UDMY
268
DELISTED
Udemy
UDMY
| $11.7M | 0.05% |
1,666,003
+437,769
| +36% | +$3.07M |
|
269
AnaptysBio
ANAB
$1.52B
| $11.6M | 0.05% |
378,452
+10,005
| +3% | +$230K |
|
270
Polaris
PII
$3.78B
| $11.6M | 0.05% |
199,179
+14,460
| +8% | +$780K |
|
271
Reynolds Consumer Products
REYN
$5.36B
| $11.6M | 0.05% |
473,003
-59,441
| -11% | -$1.35M |
|
272
Ethan Allen Interiors
ETD
$603M
| $11.5M | 0.05% |
391,769
+117,047
| +43% | +$3.46M |
|
273
Genworth Financial
GNW
$3.85B
| $11.4M | 0.05% |
1,285,684
-568,660
| -31% | -$4.69M |
|
274
Invitation Homes
INVH
$17.9B
| $11.3M | 0.05% |
386,921
+285,607
| +282% | +$8.8M |
|
275
Vistra
VST
$48.5B
| $11.2M | 0.04% |
57,076
+17,421
| +44% | +$3.45M |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q3 2025 Portfolio in Review
As of Q3 2025, Jacobs Levy Equity Management held 1,147 positions worth $25.2B, down 1.3% from $25.5B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Jacobs Levy Equity Management withdrew a net $2.05B in Q3 2025, closing 194 positions and reducing 504 holdings. Its most notable exit was Progressive, an estimated $66.7M position sold in full.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Jacobs Levy Equity Management opened a new position in Bank of America worth $45M.
- Jacobs Levy Equity Management's largest Q3 2025 buy was Bank of America: 873,228 shares worth $45M.
- Jacobs Levy Equity Management added most to Alnylam Pharmaceuticals in Q3 2025, an estimated $160M increase.
- Jacobs Levy Equity Management's biggest Q3 2025 reduction was GE Vernova, cutting an estimated $205M.
- Jacobs Levy Equity Management fully exited Progressive in Q3 2025, selling an estimated $66.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 27% of its $25.2B portfolio in Q3 2025.
- Jacobs Levy Equity Management opened 127 new positions and closed 194 in Q3 2025.
- Jacobs Levy Equity Management's portfolio value fell 1.3% quarter-over-quarter to $25.2B.
Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.